Among them, lomitapide, a microsomal TG transfer protein inhibitor, and mipomersen, an ApoB100 synthesis inhibitor, were approved by the US FDA for the treatment of FH as early as 2012 and 2013 (Raal et al., 2010; Cuchel et al., 2013), but have not yet entered the Chinese market. The gene discussed is APOB; the disease is familial hyperaldosteronism.